Ionpath
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
960 Obrien Dr, Menlo Park, California, 9...Phone Number
(833) 466-7284Website
www.ionpath.comRevenue
$8.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Ionpath
Ionpath, Inc., is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. Ionpath's MIBI (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry (IHC), enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis. With MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights for translational and clinical researchers at leading pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.Explore more
Ionpath Org Chart
JF
Vice President of Pathology
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ionpath your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Ionpath launches new products
Click to see if Ionpath had a recent Job posting/layoffs
Earning: See what the market has to say on Ionpath recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Ionpath
Check if Ionpath has recently received funding, and reach out quickly before it becomes old news!
Check out if Ionpath is spiking on competitors!
Ionpath, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Ionpath has new funding data
Recommended Actions
Find VP level buyers at Ionpath
Find 3 more new buyers
Compare Similar Companies to Ionpath
Compare insights from companies similar to Ionpath, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ionpath is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ionpath is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ionpath.
Ionpath financials insights
Gather financial insights about Ionpath, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$1M
Series B
$18M
2021
Debt
$1M
Ionpath Tech Stack
A closer look at the technologies used by Ionpath
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Research & Development, Bioengineering, Medical Research, Clinical Operations, Healthcare Technology
Open Position
Promotion
Executive Move
Lateral Move
Executive Move
Board of Directors
New Hire
Executive Move
Ionpath News & Media
Ionpath Announces the Launch of MIBIscope™ 3.0 Spatial Proteomics Imaging Platform
MENLO PARK, Calif.--(BUSINESS WIRE)--Ionpath, a leader in high-definition spatial proteomics, today announced the launch of its new MIBIscope 3.0 imaging platform. The upgraded platform includes transformative advancements that allow researchers to map complex cellular interactions within the tissue microenvironment at subcellular resolution, customize imaging conditions, and set up imaging sessions to run continuously. These upgrades build on existing capabilities of capturing and generating hIonpath Announces Executive Chair Appointment and CEO Promotion
MENLO PARK, Calif.--(BUSINESS WIRE)--Ionpath, a pioneer in high-plex spatial proteomics, today announced that Paul Davy, former Vice President of Customer Experience, has been appointed CEO of the company. Outgoing CEO David Summa is now Executive Chairman of Ionpath’s Board of Directors. Mr. Summa served as CEO at Ionpath, leading the company’s transition from a traditional hardware business to a hardware-as-service business, concluding with the recent launch of the MIBIplus service at the annIonpath Launches MIBIplus and MIBIsight, A New Service Offering and User-Friendly Bioinformatics Tools, at SITC 2023
MENLO PARK, Calif.--(BUSINESS WIRE)--Ionpath, a pioneer in high-plex spatial proteomics, today announced the launch of its new service and data analysis tools for immuno-oncology applications in basic, translational, and clinical research. The service and analysis tools will be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 1-5 in San Diego, in the Ionpath exhibit hall booth (#1107). Ionpath’s single-cell, spatial proteomics service utilIonpath Announces Shift Toward Spatial Proteomics Services Business
MENLO PARK, Calif.--(BUSINESS WIRE)--Ionpath, a pioneer in high-definition spatial proteomics, today announced a rebalancing of the company’s focus toward its Spatial Proteomics Services. The company will suspend sales of its multiplexed ion beam imaging (MIBI™) technology as a standalone platform in favor of using these instruments for its service business. Ionpath will continue to support its service customers and its installed base of instruments by selling consumables and servicing equipmen
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ionpath
Sign Up For FreeTo access detailed company insights
Ionpath, Inc., is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. Ionpath's MIBI (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry (IHC), enabling a deeper understanding of the tissue microe... Read More
